1,536 Shares in Illumina, Inc. (NASDAQ:ILMN) Acquired by Citizens Financial Group Inc. RI

Citizens Financial Group Inc. RI acquired a new stake in Illumina, Inc. (NASDAQ:ILMN) in the 4th quarter, according to its most recent disclosure with the SEC. The fund acquired 1,536 shares of the life sciences company’s stock, valued at approximately $205,000.

Other institutional investors have also recently modified their holdings of the company. Golden State Wealth Management LLC bought a new position in shares of Illumina in the fourth quarter worth $32,000. Versant Capital Management Inc lifted its holdings in shares of Illumina by 153.7% during the 4th quarter. Versant Capital Management Inc now owns 241 shares of the life sciences company’s stock worth $32,000 after acquiring an additional 146 shares during the period. Bank Julius Baer & Co. Ltd Zurich bought a new stake in shares of Illumina during the 4th quarter worth approximately $45,000. Assetmark Inc. boosted its position in shares of Illumina by 954.8% during the 4th quarter. Assetmark Inc. now owns 327 shares of the life sciences company’s stock worth $44,000 after acquiring an additional 296 shares in the last quarter. Finally, TD Private Client Wealth LLC lifted its stake in Illumina by 58.5% during the third quarter. TD Private Client Wealth LLC now owns 382 shares of the life sciences company’s stock worth $50,000 after purchasing an additional 141 shares during the last quarter. 89.42% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

A number of equities analysts have recently commented on ILMN shares. TD Cowen cut Illumina from a “buy” rating to a “hold” rating and lowered their price target for the stock from $177.00 to $140.00 in a report on Friday, February 7th. Guggenheim decreased their price target on Illumina from $170.00 to $150.00 and set a “buy” rating for the company in a research note on Friday, February 7th. Stephens reaffirmed an “overweight” rating and set a $156.00 price target on shares of Illumina in a research report on Tuesday. Robert W. Baird cut their target price on shares of Illumina from $127.00 to $90.00 and set a “neutral” rating on the stock in a research note on Wednesday, March 5th. Finally, Barclays reaffirmed an “underweight” rating on shares of Illumina in a research note on Tuesday. One equities research analyst has rated the stock with a sell rating, ten have assigned a hold rating, ten have issued a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $140.90.

Illumina Stock Performance

Shares of ILMN stock opened at $85.60 on Friday. The company has a debt-to-equity ratio of 0.63, a current ratio of 1.77 and a quick ratio of 1.42. The firm has a 50-day moving average of $113.52 and a 200-day moving average of $129.88. Illumina, Inc. has a one year low of $80.18 and a one year high of $156.66. The company has a market cap of $13.56 billion, a P/E ratio of -11.15, a P/E/G ratio of 1.60 and a beta of 1.17.

Illumina (NASDAQ:ILMN) last posted its quarterly earnings data on Thursday, February 6th. The life sciences company reported $0.86 EPS for the quarter, missing the consensus estimate of $0.92 by ($0.06). Illumina had a negative net margin of 27.95% and a positive return on equity of 13.37%. Equities research analysts forecast that Illumina, Inc. will post 4.51 EPS for the current fiscal year.

Illumina Profile

Illumina, Inc offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.